Study identifier:NIS-OGR-DUM-2010/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An NIS Registry for the Epidemiological and Scientific evaluation of EGFR mutation status in patients with newly diagnosed locally advanced or metastatic NSCLC (stage IIIB/IV non-small cell lung cancer)-REASON STUDY.
Non Small Cell Lung Cancer
N/A
No
-
All
589
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2015 by AstraZeneca
AstraZeneca
-
The primary objective of the study is to collect epidemiological data on EGFR mutation status [M+(mutation positive), M-(mutation negative)] in a population of predominantly Caucasian ethnicity, and to correlate EGFR mutation status with clinico-pathological characteristics (e.g. smoking status, sex, histology, etc). In particular, the study will aim to determine the frequency of EGFR M+ lung cancers in patients with clinico-pathological characteristics that are not commonly associated with EGFR mutation positivity (i.e., smokers, men, and non-adenocarcinoma).
Location
Location
ATHENS, Athens, Greece
Location
CRETE, Crete, Greece
Location
LARISA, LARISA, Greece
Location
PATRA, Patra, Greece
Location
THESSALONIKI, Thessaloniki, Greece
Location
Kavala, Kavala, Greece
Location
IOANNINA, Ioannina, Greece
Location
PTOLEMAIDA, Ptolemaida, Greece
Arms | Assigned Interventions |
---|---|
1 Patients with Non Small Cell Lung Cancer, visiting hospital oncology clinics | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.